Syngene

Contract manufacturing services firm Syngene International on Wednesday reported a 4 per cent decline in profit after tax to Rs 74 crore for the first quarter ended June 2022. The company had posted a PAT of Rs 77 crore in the April-June quarter of last fiscal. Its revenue from operations rose to Rs 644 crore in the first quarter against Rs 595 crore in the year-ago period, the company said in a statement. The first quarter results were against a strong quarter last year due to sales of Remdesivir, it added. Excluding the impact of Remdesivir, the underlying revenue from operations growth in the quarter stood at around 30 per cent year-on-year, it stated. "The first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. The contribution from the development and manufacturing services divisions drove the growth momentum against a low base in the previous year," Syngene International MD and CEO Jonathan Hunt ..

In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm's initiatives to overcome supply chain bottlenecks and other issues

Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive

In a Q&A, Jonathan Hunt talks about his company's capex plans and strategic initiatives going forward

Syngene International on Thursday said it has signed an agreement with Deerfield Discovery and Development Corporation (3DC)to collaborate for five years to advance therapeutic discovery projects.

While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger

The product will be launched once it receives approval from the Central Drugs Standard Control Organisation (CDSCO) next.

Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million square feet

Trading ideas by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers

Syngene, the contract research and manufacturing unit of Biocon is looking to expand its business to work on products for customers that target Indian consumers. It has signed up HerbalLife Nutrition, a nutrition company to develop nutrition based products that can be sold by the company in the country. This is the first nutrition research and development Lab in India by HerbalLife. The new facility is located in Syngene campus and has a separate Good Manufacturing Practices (GMP) formulation lab to support product testing, sampling and end-product development. The lab currently has 10 members combined from Syngene and HerbalLife. "Apart from bringing the global portfolio of products to India, we also endeavour to develop flavors that appeal to the Indian palate. Setting up the Nutrition R&D Lab in collaboration with Syngene will give us the ability to turnaround new products faster, and introduce them to the market quicker. This is the fifth dedicated centre and second for ...

The Karnataka Fire Department tweeted that it has sent over eight fire tenders to quell the blaze

Shares of the company closed at Rs 427.75 on BSE

This, because business from contract research and manufacturing services from global pharma firms increased